GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Price-to-Operating-Cash-Flow

Baudax Bio (Baudax Bio) Price-to-Operating-Cash-Flow : (As of Jun. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Price-to-Operating-Cash-Flow?

As of today (2024-06-14), Baudax Bio's share price is $0.0059. Baudax Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.34. Hence, Baudax Bio's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Baudax Bio's Price-to-Operating-Cash-Flow or its related term are showing as below:

BXRXQ's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.82
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Baudax Bio's Cash Flow from Operations per share for the three months ended in Sep. 2023 was $-0.30. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.34.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 77.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 57.90% per year.

During the past 6 years, Baudax Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 77.30% per year. The lowest was 22.30% per year. And the median was 55.20% per year.


Baudax Bio Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Baudax Bio's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Price-to-Operating-Cash-Flow Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Baudax Bio's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Baudax Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Price-to-Operating-Cash-Flow falls into.



Baudax Bio Price-to-Operating-Cash-Flow Calculation

Baudax Bio's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.0059/-5.344
=

Baudax Bio's Share Price of today is $0.0059.
Baudax Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Baudax Bio Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341